Annals of Oncology 11:1451-1462, 2000
© 2000 European Society for Medical Oncology
research-article |
Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors
An update after long-term follow-up from two centers of the European Intergroup Study EICESS
1Martin Luther University Halle-Wittenberg Germany
2Heinrich Heine University Düsseldorf Germany
3Wilhelms-University Münster Germany
4University of Leipzig Germany
5Children's Hospital, University of Southern California Los Angeles, USA
6St. Anna Kinderspital Vienna, Austria
Correspondence to: S. Burdach, MD, PhD Division of Pediatric Hematology/Oncology Children's Hospital Medical Center Martin Luther University Halle-Wittenberg 06097 Halle Germany E-mail: stefan.burdach{at}medizin.uni-halle.de
BACKGROUND: An update of results from the High Risk Protocol of the Meta-EICESS Study, conducted at the Pediatric Stem-Cell Transplant Centers of Düsseldorf and Vienna. In order to evaluate a possible therapeutic benefit after allogeneic SCT in patients with advanced Ewing tumors (AET), we compared outcome after autologous and allogeneic stem-cell transplantation (SCT).
PATIENTS AND METHODS: We analyzed 36 patients treated with the myeloablative Hyper-ME protocol (hyperfractionated total body irradiation, melphalan, etoposide ± carboplatin) between November 1986 and December 1994. Minimal follow-up for all patients was five years. All patients underwent remission induction chemotherapy and local treatment before myeloablative therapy. Seventeen of thirty-six patients had multifocal primary Ewing's tumor, eighteen of thirty-six had early, multiple or multifocal relapse, one of thirty-six patients had unifocal late relapse. Twenty-six of thirty-six were treated with autologous and ten of thirty-six with allogeneic hematopoetic stem cells. We analyzed the following risk factors, that could possibly influence the event-free survival (EFS): number of involved bones, degree of remission at time of SCT, type of graft, indication for SCT, bone marrow infiltration, bone with concomitant lung disease, age at time of diagnosis, pelvic involvement, involved compartment radiation, histopathological diagnosis.
RESULTS: EFS for the 36 patients was 0.24 (0.21) ± 0.07. Eighteen of thirty-six patients suffered relapse or died of disease, nine of thirty-six died of treatment related toxicity (DOC). Nine of thirty-six patients are alive in CR. Age 
17 years at initial diagnosis (P < 0.005) significantly deteriorated outcome. According to the type of graft, EFS was 0.25 ± 0.08 after autologous and 0.20 ± 0.13 after allogeneic SCT. Incidence of DOC was more than twice as high after allogeneic (40%) compared to autologous (19%) SCT, even though the difference did not reach significance (P = 0.08, Fisher's exact test).
CONCLUSIONS: Because of the rather short observation period, secondary malignant neoplasm (SMN) may complicate the future clinical course of some of our patients who are currently viewed as event-free survivors. EFS in AET is not improved by allogeneic SCT due to a higher complication rate. The patient group was to small to analyze for a possible graft-versus-tumor effect.
advanced Ewing tumors, allogeneic stem-cell transplantation, autologous stem-cell transplantation, IL-2 therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. HUHN, M. S. STAEGE, M. HESSE, B. LIEBIG, and S. E.G. BURDACH Cleavage of the Ewing Tumour-specific EWSR1-FLI1 mRNA by Hammerhead Ribozymes Anticancer Res, June 1, 2009; 29(6): 1901 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Oberlin, A. Rey, A. S. Desfachelles, T. Philip, D. Plantaz, C. Schmitt, E. Plouvier, O. Lejars, H. Rubie, P. Terrier, et al. Impact of High-Dose Busulfan Plus Melphalan As Consolidation in Metastatic Ewing Tumors: A Study by the Societe Francaise des Cancers de l'Enfant J. Clin. Oncol., August 20, 2006; 24(24): 3997 - 4002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby, and J. S. Whelan High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours Ann. Onc., August 1, 2006; 17(8): 1301 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hendershot Treatment Approaches for Metastatic Ewing's Sarcoma: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2005; 22(6): 339 - 352. [Abstract] [PDF]
|
|
|
|
|
|
N. Marina and P. A. Meyers High-Dose Therapy and Stem-Cell Rescue for Ewing's Family of Tumors in Second Remission J. Clin. Oncol., July 1, 2005; 23(19): 4262 - 4264. [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Verneris, A. Arshi, M. Edinger, M. Kornacker, Y. Natkunam, M. Karami, Y.-a. Cao, N. Marina, C. H. Contag, and R. S. Negrin Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells Clin. Cancer Res., June 15, 2005; 11(12): 4561 - 4570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Kolb, B. H. Kushner, R. Gorlick, C. Laverdiere, J. H. Healey, M. P. LaQuaglia, A. G. Huvos, J. Qin, H. T. Vu, L. Wexler, et al. Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults J. Clin. Oncol., September 15, 2003; 21(18): 3423 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Burdach, A. Meyer-Bahlburg, H.J. Laws, R. Haase, B. van Kaik, B. Metzner, A. Wawer, R. Finke, U. Gobel, J. Haerting, et al. High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing's Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation J. Clin. Oncol., August 15, 2003; 21(16): 3072 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bertuzzi, L. Castagna, A. Nozza, V. Quagliuolo, L. Siracusano, M. Balzarotti, S. Compasso, M. Alloisio, H. Soto Parra, and A. Santoro High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study J. Clin. Oncol., April 15, 2002; 20(8): 2181 - 2188. [Abstract] [Full Text] [PDF]
|
|